Therapeutic monoclonal antibodies for respiratory diseases:Current challenges and perspectives, March 31 – April 1, 2016, Tours, France
In: Desoubeaux , G , Reichert , J M , Sleeman , M , Reckamp , K L , Ryffel , B , Adamczewski , J P , Sweeney , T D , Vanbever , R , Diot , P , Owen , C A , Page , C , Lerondel , S , Le Pape , A & Heuze-Vourc'h , N 2016 , ' Therapeutic monoclonal antibodies for respiratory diseases : Current challenges and perspectives, March 31 – April 1, 2016, Tours, France ' , Mabs , vol. 8 , no. 6 , pp. 999-1009 . https://doi.org/10.1080/19420862.2016.1196521
Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Center of Respiratory Diseases (CEPR-INSERM U1100), the Laboratory of Excellence "MAbImprove," the GDR 3260 "Antibodies and therapeutic targeting," and the Grant Research program ARD2020 "Biotherapeutics" invited speakers from industry, academic and government organizations to present their recent research results at the Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives congress held March 31 – April 1, 2016 in Tours, France.
